טוען...
Rituximab Exhibits Altered Pharmacokinetics in Patients with Membranous Nephropathy
BACKGROUND: Rituximab (RTX) is a chimeric monoclonal anti-CD20 antibody used off-label in the treatment of membranous nephropathy (MN). Unfortunately, limited information is available on the pharmacokinetics of therapeutic proteins such as RTX in patients with glomerular kidney diseases. OBJECTIVE:...
שמור ב:
| הוצא לאור ב: | Ann Pharmacother |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6629258/ https://ncbi.nlm.nih.gov/pubmed/30293439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1060028018803587 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|